KYNTRA BIO, INC. (KYNB): M&A transaction — FibroGen completes sale of China business to AstraZeneca for ~$220M; repays $81M term loan

KYNTRA BIO, INC.

Sale price ~$220M: $85M enterprise value plus ~$135M net cash held in China.
Net cash received $210.4M; transaction costs $7.7M; net assets sold $138.9M.
Pro forma cash and equivalents rise to $145M from $23M; pro forma deficit narrows to $1.684B.
Repaid $80.9M to MSTV, including $73.7M term loan balance and $6.8M loss on debt extinguishment.
Released $142.9M deferred revenue related to China single performance obligation.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

KYNTRA BIO, INC. completed a disposition involving AstraZeneca Treasury Limited for approximately $220 million (closed 2025-08-29).

Action: disposition
Counterparty: AstraZeneca Treasury Limited
Consideration: approximately $220 million
Closing: 2025-08-29

Exact text from the filing

sold all of the issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. to AstraZeneca, for approximately $220 million

View on SEC.gov

31 m&a transactions filed in the last 30 days. Browse all m&a transactions →

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000921299-25-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.